Bevacizumab-based Chemotherapy Tailored to the Pharmacokinetics of Bevacizumab in First-line Treatment of Unresectable Metastatic Colorectal Cancer: a Randomized, Multicenter, Double-blind Phase 3 Study

Bevacizumab is a standard drug for metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy. However, inter-individual pharmacokinetic variability was observed for bevacizumab and an exposure-response relationship for efficacy was described for bevacizumab in mCRC patients treated with 1st-line bevacizumab-based chemotherapy.

开始日期2024-10-30

申办/合作机构

University Hospitals of Tours

[+15]

EUCTR2021-002563-22-FR / Not yet recruiting临床2期

Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study - SPARTANA

开始日期2021-09-13

申办/合作机构

Chu De Besançon

EUCTR2020-006046-40-FR / Not yet recruiting临床2期

Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by hypofractionated radiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study. - INTERACT-ION

开始日期2021-07-02

申办/合作机构

Chu De Besançon

100 项与 Chu De Besançon 相关的临床结果

登录后查看更多信息

0 项与 Chu De Besançon 相关的专利（医药）

登录后查看更多信息

789

项与 Chu De Besançon 相关的文献（医药）

2024-12-01·Joint Bone Spine

Interest in various treatments for osteoarthritis among the French population: A Google Trends analysis

Letter

作者: Fakih, Olivier ; Wendling, Daniel ; Verhoeven, Frank ; Prati, Clément

2024-12-01·Molecular Biology Reports

Comparison of high-risk HPV detection by the AmpFire® HPV Screening 16/18/HR technique (Atila Biosystems) and the hybrid capture 2 test (Qiagen)

Article

作者: Baraquin, Alice ; Desmarets, Maxime ; Prétet, Jean-Luc ; Diallo, Kadiatou ; Lepiller, Quentin ; Puget, Line ; Koussouri, Anais

BACKGROUNDDetection of high-risk human papillomaviruses (hrHPV) is widely used at the first line of cervical cancer screening, requiring rigorous validation of the clinical performance of commercial kits designed for this indication.METHODSPerformance of the AmpFire HPV Screening 16/18/HR test (AF, Atila Biosystems) and the Hybrid Capture 2 test (HC2, Qiagen) for detecting hrHPV was cross-compared in 200 cervical samples in our institution.RESULTSThe global percentage of agreement between the 2 techniques was 95.0% (95%CI 92-98%) with a Cohen's kappa coefficient of 0.85 (95%CI 0.75-0.94). Ten samples showed discordant results between the 2 techniques in both directions (5 HC2+/AF- and 5 HC2-/AF+). Among possible explanations for these discrepancies was the detection of HPV66 and HPV53 genotypes in two samples, since these genotypes are targeted by the Ampfire test but not by the HC2 test, as well as intrinsic differences in analytical performance to target specific genotypes.CONCLUSIONSA high level of agreement was observed between the two techniques, which encourages further testing in order to definitively validate the use of the Ampfire kit for primary cervical cancer screening.

2024-10-22·Neurology

A Multicenter Real-Life Study

Article

作者: Casez, Olivier ; Vukusic, Sandra ; Casey, Romain ; Magy, Laurent ; Defer, Gilles ; Michel, Laure ; Bourre, Bertrand ; Stankoff, Bruno ; Edan, Gilles ; Al-Khedr, Abdullatif ; Hay, Marion ; Ciron, Jonathan ; Labauge, Pierre ; Ruet, Aurélie ; Neau, Jean-Philippe ; Le Page, Emmanuelle ; Moreau, Thibault ; Laplaud, David-Axel ; Pelletier, Jean ; Clavelou, Pierre ; De Sèze, Jérôme ; Heinzlef, Olivier ; Maillart, Elisabeth ; Papeix, Caroline ; Lebrun-Frénay, Christine ; Hankiewicz, Karolina ; Mathey, Guillaume ; Moulin, Solène ; Doghri, Inès ; Tchikviladzé, Maia ; Zéphir, Hélène ; Camdessanché, Jean-Philippe ; Kerbrat, Anne ; Berger, Eric ; Wahab, Abir ; Labeyrie, Céline ; Thouvenot, Eric ; Rollot, Fabien

BACKGROUND AND OBJECTIVESAlthough rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability progression (CDP) in a cohort of patients with PPMS treated with anti-CD20 therapies compared with a weighted untreated control cohort.METHODSThis was a retrospective study using data from the French MS registry (Observatoire Français de la Sclérose En Plaques). We included patients with PPMS treated or never treated with anti-CD20 therapies from 2016 to 2021, with an Expanded Disability Status Scale score of ≤6.5 at baseline. The primary outcome was time to first CDP. The secondary outcomes were time to first relapse, MRI activity at 2 years, identification of risk factors associated with CDP, and serious infection incidence rates (IIRs). Each outcome was studied using an inverse probability of treatment weighting method. The outcomes were modeled using a weighted proportional Cox model for the time-to-event outcomes and by a logistic regression regarding the MRI activity.RESULTSA total of 1,184 patients (426 treated and 758 untreated) fulfilled the inclusion criteria. Median age (Q1-Q3) was 56 years (49.3-63.8), and 52.7% were female. Among treated patients, 295 received rituximab, whereas 131 received ocrelizumab. At baseline, anti-CD20-treated patients were younger (median 51.9 vs 58.6 years, Cohen d = 0.683) and had more active disease (54.5 vs 27.8%, Cohen d = 0.562). 91.6% were drug-naive at inclusion. In time to first CDP analysis, no statistical significance was observed (hazard ratio [HR], 1.13; 95% CI 0.93-1.36, p = 0.2113). In time to first relapse analysis, a nonsignificant trend toward fewer patients relapsing in the treated group was observed (HR 0.83; 95% CI 0.48-1.28, p = 0.0809). For MRI activity, no significant difference was found between the 2 groups. Risk factors associated with CDP in the treated group were male sex and MS duration. IIR was 6.67 (95% CI 3.12-14.25) per 100 person-years in the treated group vs 2.67 (95% CI 0.80-8.86) in the untreated group.DISCUSSIONTime to first CDP was not different between anti-CD20 treated and untreated patients with PPMS. Although our study is retrospective and mainly included patients treated by rituximab, our results indicate that there should be a constant evaluation of all available data to ascertain the best risk/benefit ratio for patients with PPMS.CLASSIFICATION OF EVIDENCEThis study provides Class III evidence that anti-CD20 therapy of previously untreated patients with PPMS was not superior to no therapy in delaying time to first CDP.

100 项与 Chu De Besançon 相关的药物交易

登录后查看更多信息

100 项与 Chu De Besançon 相关的转化医学

登录后查看更多信息